DERMATA THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2023-09-30 · SEC EDGAR
ComparingFY2023 (Q4) vs FY2022 (Q4)
Revenue
$93K
↑+331.8% +$71Kvs FY2022 (Q4)
Gross Profit
$93K
↑+331.8% +$71Kvs FY2022 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2023 (Q4) | FY2022 (Q4) |
|---|---|---|
| Revenue | $93K | $21K |
| COGS | $0 | $0 |
| Gross Profit | $93K | $21K |
| R&D | $903K | $2M |
| SG&A | $0 | $0 |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · DRMA · Comparing FY2023 (Q4) vs FY2022 (Q4)